Literature DB >> 7574519

Bacterial activity of a new antiulcer agent, ecabet sodium, against Helicobacter pylori under acidic conditions.

K Shibata1, Y Ito, A Hongo, A Yasoshima, T Endo, M Ohashi.   

Abstract

Helicobacter pylori NCTC 11637, which is nonviable at pH 3.0, became viable after addition of 10 mM urea owing to ammonia production by urease. In a buffer supplemented with urea, ecabet sodium decreased both the production of ammonia and the number of viable cells of H. pylori NCTC 11637 and changed the bacteria from the bacilliform to the horseshoe or doughnut shape in a concentration-dependent manner. In particular, ecabet sodium (2 and 4 mg/ml) decreased the number of viable cells below the control level. Benzohydroxamic acid, a urease inhibitor, also caused a decrease in ammonia production accompanied by a decrease in the number of viable cells and changed the morphological form at pH 3.0, but the number of viable cells was not lowered below the control level. In buffers at various pHs without urea, ecabet sodium showed a concentration-dependent bactericidal effect on H. pylori at pHs 4.0 and 5.0 but not at pHs 6.0 and 7.0 while benzohydroxamic acid caused only a slight decrease in the number of viable cells at pH 4.0. These results suggest that ecabet sodium has strong bactericidal activity in addition to its urease-inhibiting activity under acidic conditions.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7574519      PMCID: PMC162730          DOI: 10.1128/AAC.39.6.1295

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  Meta-analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori.

Authors:  N Chiba; B V Rao; J W Rademaker; R H Hunt
Journal:  Am J Gastroenterol       Date:  1992-12       Impact factor: 10.864

2.  [Polymorphism in Helicobacter pylori--a key function in recurrence of infection?].

Authors:  G Bode; P Malfertheiner; A Ströhle; F Mauch; M Nilius; H Ditschuneit
Journal:  Med Klin (Munich)       Date:  1992-04-15

3.  Unidentified curved bacilli on gastric epithelium in active chronic gastritis.

Authors:  J R Warren; B Marshall
Journal:  Lancet       Date:  1983-06-04       Impact factor: 79.321

4.  Effects of the new anti-ulcer drug ecabet sodium (TA-2711) on pepsin activity. II. Interaction with substrate protein.

Authors:  Y Ito; Y Onoda; S Nakamura; K Tagawa; T Fukushima; Y Sugawara; O Takaiti
Journal:  Jpn J Pharmacol       Date:  1993-06

5.  Antiulcer activity of dehydroabietic acid derivatives.

Authors:  H Wada; S Kodato; M Kawamori; T Morikawa; H Nakai; M Takeda; S Saito; Y Onoda; H Tamaki
Journal:  Chem Pharm Bull (Tokyo)       Date:  1985-04       Impact factor: 1.645

6.  Morphological forms and viability of Campylobacter species studied by electron microscopy.

Authors:  L K NG; R Sherburne; D E Taylor; M E Stiles
Journal:  J Bacteriol       Date:  1985-10       Impact factor: 3.490

7.  Reinfection or recrudescence after apparently successful eradication of Helicobacter pylori infection: implications for treatment of patients with duodenal ulcer disease.

Authors:  G D Bell; K U Powell; S M Burridge; G Harrison; B Rameh; J Weil; P W Gant; P H Jones; J E Trowell
Journal:  Q J Med       Date:  1993-06

8.  Metabolic fate of a new anti-ulcer drug (+)-(1R,4aS,10aR)-1,2,3,4,4a,9,10,10a- octahydro-1,4a-dimethyl-7-(1-methylethyl)-6-sulfo-1- phenanthrenecarboxylic acid 6-sodium salt pentahydrate (TA-2711). II. Distribution in the rat stomach.

Authors:  Y Ito; Y Sugawara; O Takaiti; S Nakamura
Journal:  J Pharmacobiodyn       Date:  1991-09

9.  Effects of the new anti-ulcer drug ecabet sodium (TA-2711) on pepsin activity. I. Inactivation of enzyme protein.

Authors:  Y Ito; S Nakamura; Y Onoda; Y Sugawara; O Takaiti
Journal:  Jpn J Pharmacol       Date:  1993-06

10.  Campylobacter pyloridis and gastritis: association with intercellular spaces and adaptation to an environment of mucus as important factors in colonization of the gastric epithelium.

Authors:  S L Hazell; A Lee; L Brady; W Hennessy
Journal:  J Infect Dis       Date:  1986-04       Impact factor: 5.226

View more
  10 in total

1.  Effect of ecabet sodium on Helicobacter pylori adhesion to gastric epithelial cells.

Authors:  S Hayashi; T Sugiyama; A Yachi; K Yokota; Y Hirai; K Oguma; N Fujii
Journal:  J Gastroenterol       Date:  1997-10       Impact factor: 7.527

2.  Effects of ecabet sodium, a novel gastroprotective agent, on mucin metabolism in rat gastric mucosa.

Authors:  T Ichikawa; K Ishihara; H Hayashida; H Hiruma; K Saigenji; K Hotta
Journal:  Dig Dis Sci       Date:  2000-03       Impact factor: 3.199

3.  In vitro and in vivo activities of tea catechins against Helicobacter pylori.

Authors:  K Mabe; M Yamada; I Oguni; T Takahashi
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

4.  Safety and tolerability of bismuthyl ecabet suspension, a novel anti-ulcer agent, following single and multiple oral dose administration in healthy Chinese subjects.

Authors:  Yongqing Wang; Nana Tang; Ling Meng; Peipei Zhang; Kun Xu; Ningling Jiang; Haibo Zhang; Ning Ou; Deqin Wu; Anjiu Chen; Xiyong Zhang; Ruihua Shi
Journal:  Clin Drug Investig       Date:  2012-04-01       Impact factor: 2.859

5.  Sofalcone, a mucoprotective agent, increases the cure rate of Helicobacter pylori infection when combined with rabeprazole, amoxicillin and clarithromycin.

Authors:  Hajime Isomoto; Hisashi Furusu; Ken Ohnita; Chun-Yang Wen; Kenichiro Inoue; Shigeru Kohno
Journal:  World J Gastroenterol       Date:  2005-03-21       Impact factor: 5.742

6.  H pylori eradication: a randomized prospective study of triple therapy with or without ecabet sodium.

Authors:  Hyung Wook Kim; Gwang Ha Kim; Jong Yun Cheong; Ung Suk Yang; Seung Keun Park; Chul Soo Song; Dae Hwan Kang; Geun Am Song
Journal:  World J Gastroenterol       Date:  2008-02-14       Impact factor: 5.742

7.  Antimicrobial activities of Eugenol and Cinnamaldehyde against the human gastric pathogen Helicobacter pylori.

Authors:  Shaik Mahaboob Ali; Aleem A Khan; Irshad Ahmed; M Musaddiq; Khaja S Ahmed; H Polasa; L Venkateswar Rao; Chittoor M Habibullah; Leonardo A Sechi; Niyaz Ahmed
Journal:  Ann Clin Microbiol Antimicrob       Date:  2005-12-21       Impact factor: 3.944

8.  Prospective multi-center trial for the efficacy of ecabet sodium on the relief of dyspepsia in korean patients with chronic gastritis.

Authors:  Hak Yang Kim; Ki-Baik Hahm; Myung-Gyu Choi; Jong-Sun Rew; Sang-Young Seol; Hoon-Jai Chun; Oh-Young Lee; Weon-Seon Hong
Journal:  J Clin Biochem Nutr       Date:  2007-11       Impact factor: 3.114

9.  Growth inhibitory, bactericidal, and morphostructural effects of dehydrocostus lactone from Magnolia sieboldii Leaves on antibiotic-susceptible and -resistant strains of Helicobacter pylori.

Authors:  Hyun-Kyung Lee; Ha Eun Song; Haeng-Byung Lee; Cheol-Soo Kim; Mamoru Koketsu; Luong Thi My Ngan; Young-Joon Ahn
Journal:  PLoS One       Date:  2014-04-18       Impact factor: 3.240

10.  Design, Synthesis and Pharmacological Evaluation of Three Novel Dehydroabietyl Piperazine Dithiocarbamate Ruthenium (II) Polypyridyl Complexes as Potential Antitumor Agents: DNA Damage, Cell Cycle Arrest and Apoptosis Induction.

Authors:  Haoran Wang; Jianhua Wei; Hong Jiang; Ye Zhang; Caina Jiang; Xianli Ma
Journal:  Molecules       Date:  2021-03-07       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.